Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC)
October 01 2021 - 8:00AM
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage
biotechnology company pioneering a new class of immuno-oncology
agents that combine the targeting precision of antibodies with the
power of both the innate and adaptive immune systems, today
announced that it will be presenting three abstracts at the 2021
Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting,
which is being held from Nov. 10-14, both virtually and in person
in Washington, D.C.
The three poster presentations highlight assets in Bolt’s
preclinical pipeline, including two Boltbody™
immune stimulating antibody conjugate (ISAC) candidates and an
agonist antibody. BDC-2034 is a Boltbody ISAC targeting CEA, and
the other Boltbody ISAC program targets PD-L1. The company’s
proprietary agonist antibody targets Dectin-2 (also known as TAM1).
Information about these presentations can be found below and on the
2021 SITC Annual Meeting website.
Title: BDC-2034: Discovery of a CEA-targeting
Immune-Stimulating Antibody Conjugate (ISAC) for Solid
TumorsPresenter: William G. Mallet,
Ph.D.Poster Number: 784 Details:
Saturday, Nov. 13, 2021, 7:00 a.m. - 8:30 p.m. EST, Poster Hall
Title: Dectin-2, a novel target for tumor
macrophage reprogramming in cancer
immunotherapyPresenter: Justin A. Kenkel,
Ph.D.Poster Number: 862 Details:
Saturday, Nov. 13, 2021, 7:00 a.m. - 8:30 p.m. EST, Poster Hall
Title: PD-L1-targeted ISAC combines myeloid
cell activation, immune-checkpoint inhibition and ADCP to improve
anti-tumor efficacy over anti-PD-L1 antibodies in preclinical
modelsPresenter: Marcin Kowanetz,
Ph.D.Poster Number: 782 Details:
Saturday, Nov. 13, 2021, 7:00 a.m. - 8:30 p.m. EST, Poster Hall
About the Boltbody™ Immune-Stimulating Antibody
Conjugate (ISAC) Platform
ISACs are a new category of immunotherapy that combines the
precision of antibody targeting with the strength of the innate and
adaptive immune systems. Boltbody ISACs are comprised of three
primary components: a tumor-targeting antibody, a non-cleavable
linker, and a proprietary immune stimulant to activate the
patient’s innate immune system. By initially targeting a single
marker on the surface of a patient’s tumor cells, an ISAC can
create a new immune response by activating and recruiting myeloid
cells. The activated myeloid cells start a feed-forward loop by
releasing cytokines and chemokines, chemical signals that attract
other immune cells and lower the activation threshold for an immune
response. This reprograms the tumor microenvironment and invokes an
adaptive immune response that targets the tumor, with the goal of
durable responses for patients with cancer.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology
company pioneering a new class of immuno-oncology agents that
combine the targeting precision of antibodies with the power of
both the innate and adaptive immune systems. Bolt’s lead candidate,
BDC-1001, is a BoltbodyTM Immune-stimulating Antibody Conjugate
(ISAC) comprised of a HER2-targeting biosimilar of trastuzumab
conjugated with a non-cleavable linker to one of Bolt’s proprietary
TLR7/8 agonists for the treatment of patients with HER2-expressing
solid tumors. Bolt is also advancing BDC-2034, a Boltbody ISAC
targeting CEA, and a pipeline of early-stage immuno-oncology
products. To learn more about Bolt Biotherapeutics, please visit
www.boltbio.com.
Investor Relations and Media Contacts:Karen L.
BergmanVice President, Communications and Investor RelationsBolt
Biotherapeutics, Inc.650-665-9295kbergman@boltbio.com
Sarah McCabeStern Investor Relations,
Inc.212-362-1200sarah.mccabe@sternir.com
Maggie Beller or David SchullRusso Partners,
LLC646-942-5631maggie.beller@russopartnersllc.comdavid.schull@russopartnersllc.com
Bolt Biotherapeutics (NASDAQ:BOLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bolt Biotherapeutics (NASDAQ:BOLT)
Historical Stock Chart
From Apr 2023 to Apr 2024